Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

15.06 -0.32 (-2.08%)

Delayed Quote Updated: 11:49 AM EST, Nov 11, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	18,045
Open	15.17
Bid (Size)	15.03 (200)
Ask (Size)	15.18 (200)
Prev. Close	15.38
Today's Range	14.81 - 15.20
52wk Range	9.770 - 16.33
Shares Outstanding	871,256,270
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

International Companies Present at the Deutsche Bank ADR Virtual Investor Conference, November 12

November 10, 2026

B2i Digital, Inc. invites investors to the Deutsche Bank ADR Virtual Investor Conference, a B2i Digital Featured Conference, taking place on Thursday, November 12, 2026, and hosted by Virtual Investor...

Via B2i Digital

UPDATE – International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 12, 2026

November 09, 2026

From Virtual Investor Conferences

Via GlobeNewswire

Performance

52-Week Range 7.8% below 52-week high

15.06

9.7752W Low 16.3352W High

1 Week 2.7% below 1-week high

13.691W Low 15.481W High

HUTCHMED (China) Limited - American Depositary Shares (HCM) traded between $9.77 and $16.33 over the past 52 weeks and last traded at $15.06, 7.8% below its 52-week high. Over the past week it ranged between $13.69 and $15.48.

Past 12 Months

+8.2%

+10.1%

+20.8%

+18.9%

+10.3%

-0.2%

1W +$1.14

1M +$1.38

3M +$2.59

6M +$2.39

YTD +$1.41

1Y -$0.03

HCM was -0.2% over the past year, +18.9% over six months, +10.3% year to date, +8.2% in the last week.

12 Months vs Market

HCM

-0.2%

DIA

+10.4%

SPY

+11.6%

QQQ

+11.3%

IWM

+15.9%

Over the past 12 months HCM returned -0.2% versus DIA (Dow) +10.4%, SPY (S&P 500) +11.6%, QQQ (Nasdaq 100) +11.3% and IWM (Russell 2000) +15.9%.

Volume & Liquidity 0.26× 3-mo avg

Today 18,045 3-mo avg 70.0K

85.1K

50.6K

70.0K

61.4K

YTD

50.7K

47.6K

HCM most recently traded 18,045 shares against a 3-month average daily volume of 70.0K.

More News

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 12, 2026

November 05, 2026

From Virtual Investor Conferences

Via GlobeNewswire

HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia

November 04, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan

November 01, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia

October 28, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer

October 26, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026

October 26, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine

October 25, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

October 20, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer

September 28, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors

September 27, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026

September 23, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy ↗

September 03, 2026

Via MarketBeat

HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy

September 03, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China

August 30, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma

August 27, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®

August 16, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED H1 Earnings Call Highlights ↗

July 30, 2026

Via MarketBeat

HUTCHMED Reports 2026 Interim Results

July 30, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification

July 02, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED to Announce 2026 Half-Year Financial Results

June 30, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026

June 24, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress

June 11, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting

May 21, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

Frequently Asked Questions

Is HUTCHMED (China) Limited - American Depositary Shares publicly traded?

Yes, HUTCHMED (China) Limited - American Depositary Shares is publicly traded.

What exchange does HUTCHMED (China) Limited - American Depositary Shares trade on?

HUTCHMED (China) Limited - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for HUTCHMED (China) Limited - American Depositary Shares?

The ticker symbol for HUTCHMED (China) Limited - American Depositary Shares is HCM on the Nasdaq Stock Market

What is the current price of HUTCHMED (China) Limited - American Depositary Shares?

The current price of HUTCHMED (China) Limited - American Depositary Shares is 15.06

When was HUTCHMED (China) Limited - American Depositary Shares last traded?

The last trade of HUTCHMED (China) Limited - American Depositary Shares was at 11/11/26 11:49 AM ET

What is the market capitalization of HUTCHMED (China) Limited - American Depositary Shares?

The market capitalization of HUTCHMED (China) Limited - American Depositary Shares is 13.12B

How many shares of HUTCHMED (China) Limited - American Depositary Shares are outstanding?

HUTCHMED (China) Limited - American Depositary Shares has 13B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.